Related Experiment Video
Updated: May 23, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYC
Hannah T Rosen1,2,3,4, Kelvin Li1,4, Erin L Li1,4
1Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA.
Abstract:
While MYC is a significant oncogenic transcription factor driver of cancer, directly targeting MYC has remained challenging due to its intrinsic disorder and poorly defined structure, deeming it "undruggable." Whether transient pockets formed within intrinsically disordered and unstructured regions of proteins can be selectively targeted with small molecules remains an outstanding challenge. Here, we developed a bespoke stereochemically-paired spirocyclic oxindole aziridine covalent library and screened this library for degradation of MYC. Through this screen, we identified a hit covalent ligand KL2-236, bearing a unique sulfinyl aziridine warhead, that engaged MYC in vitro as pure MYC/MAX protein complex and in situ in cancer cells to destabilize MYC, inhibit MYC transcriptional activity and degrade MYC in a proteasome-dependent manner through targeting intrinsically disordered C203 and D205 residues. Notably, this reactivity was most pronounced for specific stereoisomers of KL2-236 with a diastereomer KL4-019 that was largely inactive. Mutagenesis of both C203 and D205 completely attenuated KL2-236-mediated MYC degradation. We have also optimized our initial KL2-236 hit compound to generate a more durable MYC degrader KL4-219A in cancer cells. Our results reveal a novel ligandable site within MYC and indicate that certain intrinsically disordered regions within high-value protein targets, such as MYC, can be interrogated by isomerically unique chiral small molecules, leading to destabilization and degradation.
Insights
Scientists developed a novel covalent ligand that targets and degrades the oncogenic MYC protein by engaging intrinsically disordered regions. This breakthrough offers a new strategy for targeting previously "undruggable" cancer drivers.
Area of Science:
- Oncology
- Chemical Biology
- Structural Biology
Background:
- MYC is a key oncogenic transcription factor driving cancer, but its disordered structure makes it difficult to target.
- Developing small molecules to target transient pockets in intrinsically disordered proteins is a significant challenge.
Purpose of the Study:
- To develop and screen a covalent ligand library for MYC degradation.
- To identify and characterize novel small molecules that can target and destabilize MYC.
Main Methods:
- A bespoke stereochemically-paired spirocyclic oxindole aziridine covalent library was synthesized and screened.
- In vitro and in situ assays were used to assess MYC engagement, destabilization, and degradation.
- Site-directed mutagenesis was employed to validate target residues.
Main Results:
- A covalent ligand, KL2-236, was identified that engages MYC and induces proteasome-dependent degradation.
- KL2-236 targets intrinsically disordered residues C203 and D205, with specific stereoisomers showing enhanced activity.
- An optimized MYC degrader, KL4-219A, was developed.
Conclusions:
- Intrinsically disordered regions of MYC can be targeted by specific chiral small molecules.
- This work reveals a novel ligandable site in MYC and provides a new therapeutic strategy for MYC-driven cancers.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Drugs that Destabilize Microtubules
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Mutagenicity and Carcinogenicity

